Our pipeline is built on small molecule, orally available therapies designed to bind to their targets with greater precision and affinity than other kinase inhibitors. By precisely targeting the cell signaling pathways that drive cancer growth and progression, we have selected each drug candidate in our pipeline for its potential to be a best-in-class therapy.
TRIDENT-1: Advanced NSCLC (ROS1) And Solid Tumors (NTRK)
CARE: Pediatric Advanced Solid Tumors
TRIDENT-2: KRAS-Targeting Combination
SHIELD-1: Advanced Solid Tumors
SHIELD-2: EGFR Combination
SWORD-1: Advanced Solid Tumors
FORGE-1: Advanced NSCLC
p21 Activated Kinase
Multiple GTPase Oncology Targets
1Partnered with Zai Lab in Greater China; Turning Point retains worldwide rights outside of Greater China.
2Turning Point retains worldwide rights.